Kamada (KMDA) Short term Debt (2012 - 2026)
Kamada's (KMDA) quarterly Short term Debt came in at $6.0 million in Q2 2026, down 38.77% on a YoY basis from $9.8 million in Q2 2025, and down 43.33% quarter-over-quarter from $10.6 million in Q1 2026.
Analysis
Kamada (KMDA) Short term Debt (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Short term Debt for 15 consecutive years, with $6.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Short term Debt fell 38.77% year-over-year to $6.0 million; the trailing twelve-month figure through Jun 2026 stood at $6.0 million (down 38.77% YoY), and the FY2025 full-year result was $9.9 million, down 2.53% from the prior year.
- Short term Debt eased to $6.0 million in Q2 2026 per KMDA's latest filing, from $10.6 million in the prior quarter.
- Across five years, Short term Debt topped out at $29.7 million in Q4 2022 and bottomed at $6.0 million in Q2 2026.
- Historically, Short term Debt has averaged $15.7 million across 5 years, with a median of $12.8 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Short term Debt soared 48159.62% in 2022, then sank 55.87% in 2024.
- Over 5 years, Short term Debt stood at $29.7 million in 2022, then slumped by 49.52% to $15.0 million in 2023, then sank by 32.11% to $10.2 million in 2024, then dropped by 2.53% to $9.9 million in 2025, then tumbled by 39.22% to $6.0 million in 2026.
- According to Business Quant data, Short term Debt over the past three periods registered $6.0 million, $10.6 million, and $9.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.03 Mn |
| Mar 31, 2026 | 10.64 Mn |
| Dec 31, 2025 | 9.92 Mn |
| Sep 30, 2025 | 10.59 Mn |
| Jun 30, 2025 | 9.85 Mn |
| Mar 31, 2025 | 10.89 Mn |
| Dec 31, 2024 | 10.18 Mn |
| Sep 30, 2024 | 9.48 Mn |
| Jun 30, 2024 | 12.61 Mn |
| Mar 31, 2024 | 12.98 Mn |
| Dec 31, 2023 | 15.00 Mn |
| Sep 30, 2023 | 15.99 Mn |
| Jun 30, 2023 | 25.08 Mn |
| Mar 31, 2023 | 29.41 Mn |
| Dec 31, 2022 | 29.71 Mn |
| Sep 30, 2022 | 25.10 Mn |
| Jun 30, 2022 | 20.12 Mn |
| Mar 31, 2022 | 19.10 Mn |
| Dec 31, 2021 | 17.99 Mn |
| Sep 30, 2021 | 52,000.00 |